by Eric Christianson | Dec 26, 2018 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Orthostasis risk with SGLT-2 Inhibitors is a potential minor concern, particularly in our geriatric population. While a drop in blood pressure can be a good thing for a significant chunk of diabetes patients, that potential modest drop can lead to an increased...
by Eric Christianson | Nov 23, 2014 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
What to do with an A1C ? For the experienced clinician, this is a very simple question, but I occasional see orders for A1C’s at a rate more frequently than every three months. Remember that it is basically an average blood sugar over a period of approximately...
by Eric Christianson | Dec 5, 2013 | Educational Case Studies For Pharmacists, Endocrine Case Studies
In making some of these decisions about medication changes, there isn’t always a perfect answer, and people disagree, but I didn’t write this post to tell you that people disagree – hopefully most of you have figured that out by now! Anyway, here’s a brief overview of...
by Eric Christianson | Nov 30, 2013 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
I’m going to cover sulfonylureas tonight; this class is a mainstay in the treatment Type 2 diabetes. Other than metformin, these drugs are probably the most frequent oral class used. The most frequent names that come to mind are glipizide, glimepiride, and...
by Eric Christianson | Nov 29, 2013 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Today, it’s the DDP-4 inhibitors! DPP-4 inhibitors can be expensive which may limit their use from time to time. These drugs work to increase the amount of incretin in the body. You can look back at my post on Byetta/Victoza which should be under the diabetes...
